Clinical Trials

We are currently participating in the following clinical trials:
(Click on trials for additional information from the National Institutes of Health.)

ALZHEIMER'S DISEASE STUDIES

• EMBARK: A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
Multi-center study to evaluate the long-term safety and tolerability of aducanumab for those who had been part of previous aducanumab prior to discontinuation by sponsor.
Sponsor: Biogen
Enrollment period: By Invitation

• ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
The study is designed to evaluate safety and efficacy of ATH-1017 in mild to moderate AD subjects, with double-blind, parallel-arm treatment duration of 26 weeks, and based on clinical diagnostic criteria of Alzheimer's disease.
Sponsor: Athira Pharmaceuticals
Enrollment period: Open

• GRADUATE: Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. The primary efficacy assessment will be performed at the end of the double blind period at week 116. Participants will then be offered to enter into an open-label extension (OLE)
Sponsor: Roche Pharmaceutical
Enrollment period: Follow-up

• CLARITY: A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease
This Double Blind study will be conducted to evaluate the efficacy of BAN2401 in participants with early Alzheimer's disease (EAD). This study will also evaluate the long-term safety and tolerability of BAN2401 in participants with EAD in the Extension Phase.
Sponsor: Eisai and Biogen
Enrollment period: Open

• DAYBREAK Study: Study of LY3314814 in Mild Alzheimer's Dementia
Multicenter, randomized, parallel-group, 78-week double blind, placebo-controlled, study of LY3314814 in patients with mild Alzheimer's dementia, followed by a 78-week delayed-start period. LY3314814 is a brain-permeable inhibitor being developed for the modification of the clinical course of Alzheimer's disease by slowing disease progression in patients diagnosed with early Alzheimer's dementia.
Sponsor: Eli Lilly & Co
Enrollment period: Closed

• Engage Study: A Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE)
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease with administration of Aducanumab IV monthly for 2 years, followed with open extension study.
Sponsor: Biogen
Enrollment period: Completed

• SERENE Study: Treatment of Agitation and Aggression in Alzheimer's Disease
Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's disease.
Sponsor: ACADIA Pharmaceuticals
Enrollment period: Completed

• Mission AD1: A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease
Multicenter, double-blind, placebo-controlled, parallel group, in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety of Elenbecestat.
Sponsor: Eisai Co
Enrollment period: Closed

• Trial of Verubecestat in Participants With Prodromal Alzheimer's Disease (APECS)
Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 in Subjects With Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD), for 2 year, followed with 5 years of open label extension.
Sponsor: Merck Sharp & Dohme Corp
Enrollment period: Closed

• TRIUMPH, a long-term, real-world evidence study of Emgality (galcanezumab)
The objective of the TRIUMPH study (Preventive Treatment of Migraine: Outcomes for Patients in Real-World Healthcare Systems) is to evaluate the real-world effectiveness of Emgality, in comparison to other preventive treatments for migraine, among people receiving routine medical care who are switching or beginning a new prescription treatment for migraine prevention.
Sponsor: Eli Lilly & Co
Enrollment period: Open

• PROMISE 1 STUDY: A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
To evaluate ALD403 in patients with Frequent Episodic Migraines via IV every three months for one year. ALD403 is a CGRP antagonist for the prophylaxis of migraines. CGRP is thought to play an important role in migraine.
Sponsor: Alder
Enrollment period: Completed

• Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis
Sponsor: Acadia Pharmaceutical
Enrollment period: Open

• Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components
This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2 clinical trial of JM-010 in patients with Parkinsons' Disease with Off period
Sponsor: Bukwang Pharmaceutical
Enrollment period: Open

• Twelve Month Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)
Sponsor: Acorda Therapeutics
Enrollment period: Completed

• PASSAGE STUDY: Study in Patients With Multiple Sclerosis Treated with Fingolimod
Study in patients with relapsing forms of MS, either newly treated with Fingolimod or receiving another disease-modifying therapy, to further explore the incidence of selected safety related outcomes and to further monitor the overall safety profile of Fingolimod under conditions of routine medical practice.
Sponsor: Novartis Pharmaceuticals
Enrollment period: Open